Formulation: 50 mM Tris-HCl (pH 7.5), with 200 mM sodium chloride, 20% glycerol, and 1 mM DTT
Formula Weight: 0
Shelf life (days): 365
Notes: Casitas B-lineage lymphoma proto-oncogene B (CBL-B) is an E3 ubiquitin ligase and a member of CBL RING-type E3 ubiquitin ligases.{72457,72458} It is composed of an N-terminal tyrosine kinase-binding domain, a helix linker region, and a RING finger domain, which is necessary for CBL-B homodimerization and heterodimerization with the related homolog c-Cbl, and a C-terminal region containing proline- and tyrosine-rich motifs and a ubiquitin-association domain.{72458} CLB-B is autoinhibited by its helix linker region but folds into the active conformation following tyrosine 371 phosphorylation by various kinases.{72459} CBL-B is ubiquitously expressed but primarily found in leukocytes and is found in the cytoplasm.{72457} It has roles in negatively regulating immune cell responses, preventing autoimmune activity, and promoting immune tolerance by targeting receptor and non-receptor tyrosine kinase signaling proteins for proteasomal degradation.{72457,53165} Knockout of cblb increases the percentage of natural killer (NK) cells expressing Ifn-γ, as well as decreases tumor volume and number of total metastases, in a B16/F10 murine melanoma model of metastasis.{53165} Knockout of Cblb increases serum IgG levels, as well as induces Cd28-independent lymphocyte hyperproliferation and B and T cell infiltration into the pancreas, salivary glands, and lungs, in mice.{72460} CBL-B levels are decreased in T cell lymphocytes isolated from patients with systemic lupus erythematosus (SLE).{72461} Cayman's CLB-B Substrate-binding Domain (human, recombinant) protein has a calculated molecular weight of 48.2 kDa.
Deutsch
English
